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MaBicuspid aortic valve (BAV) is the most common adult congenital heart defect and is found in 0.5% to 2.0% of the
general population. The term “BAV” refers to a heterogeneous group of disorders characterized by diverse aortic valve
malformations with associated aortopathy, congenital heart defects, and genetic syndromes. Even after decades of
investigation, the genetic determinants of BAV and its complications remain largely undeﬁned. Just as BAV phenotypes
are highly variable, the genetic etiologies of BAV are equally diverse and vary from complex inheritance in families to
sporadic cases without any evidence of inheritance. In this paper, the authors discuss current concepts in BAV genetics
and propose a roadmap for unraveling unanswered questions about BAV through the integrated analysis of genetic
and clinical data. (J Am Coll Cardiol 2014;64:832–9) © 2014 by the American College of Cardiology Foundation.T he most common adult congenital heartdefect, a bicuspid aortic valve (BAV), isfound in 0.5% to 2.0% of the general popu-
lation (1,2), with a higher prevalence in men. BAVs
result from abnormal aortic cusp formation during
valvulogenesis, in which adjacent cusps fuse into a
single cusp that is bigger than its counterpart but
smaller than 2 normal cusps combined (2). Overall,
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ABB R E V I A T I O N S
AND ACRONYMS
BAV = bicuspid aortic valve
BAVCon = International
Bicuspid Aortic Valve
Consortium
GWA = genome-wide
association
LVOT = left ventricular outﬂow
tract
TAAD = thoracic aortic
aneurysms and dissections
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833families to sporadic cases without evidence of inher-
itance (3).
CURRENT KNOWLEDGE OF THE GENETICS
OF BICUSPID AORTIC VALVE
GENETIC SYNDROMES. Although most patients with
BAV have no extracardiac abnormalities, BAV also
occurs as a component of known genetic syndromes
(Table 1). The highest penetrance of BAV for a genetic
syndrome occurs in women with Turner syndrome,
which is caused by partial or complete absence of one
X chromosome in women. BAV appears in >30% of
women with Turner syndrome, and the prevalence of
associated coarctation, aortic aneurysms, and acute
aortic dissections exceeds that in sporadic BAV cases
(4). In the general population, BAV is more prevalent
in men (1% to 2%) than women (0.5%) (5), suggesting
that the loss of genes on the X chromosome may
predispose to BAV formation. The genes responsible
for this effect have not been identiﬁed.
CONGENITAL HEART DEFECTS. Although the ge-
netic links remain unknown, BAV is also seen with
some congenital heart disorders involving the left
ventricular outﬂow tract (LVOT), such as hypoplastic
left heart syndrome, coarctation of the aorta, and
some ventricular septal defects (6–8). Hypoplastic
left heart syndrome and coarctation are signiﬁcantly
enriched among primary relatives of patients with
BAV, and according to linkage analysis, mutations in
the same genes probably caused some cases of hy-
poplastic left heart syndrome and BAV (9). One
possible interpretation of these observations is that
LVOT morphology and obstruction may also inﬂu-
ence aortic valve development because of alterations
in blood ﬂow or shear stress (10).
FAMILIAL INHERITANCE. BAV occasionally demon-
strates complex inheritance in large families without
syndromic features. Autosomal-dominant transmis-
sion of BAV was observed in some 3-generation
pedigrees, but no single-gene model clearly explains
BAV inheritance (11–13). The prevalence of BAV
stands nearly 10-fold higher in primary relatives of
patients with BAV than in the general population (1).
Inheritance is observed in >50% of families if asso-
ciated nonvalvular complications are involved, such
as aortic coarctation, thoracic aortic aneurysms, and
mitral valve or ventricular septal defects, which are
each found in 10% of family members (14). The her-
itability of BAV has been estimated to be as high as
0.89 in these studies, and multiple genetic alleles can
interact to cause BAV or different congenital heart
defects without BAV in the same family. Genetic,epigenetic, and environmental modiﬁers may
be responsible for the variable penetrance
and phenotypic expression.
Through linkage analysis of BAV pedigrees,
investigators have uncoveredmultiple genetic
loci for BAV. The most signiﬁcantly associated
genes were located on chromosomes 3p22
(TGFBR2), 5q15-21, 9q22.33 (TGFBR1), 9q34-
35 (NOTCH1), 10q23.3 (ACTA2), 13q33-qter,
15q25-q26.1, 17q24 (KCNJ2), and 18q, with a
maximal logarithm of odds score of 3.8
on chromosome 18q22.1 (13,15,16). Most fa-
milies were identiﬁed because of thoracic aortic
aneurysms and dissections (TAAD); BAV was found
incidentally in some patients.
These studies, along with the diverse genetic
syndromes associated with BAV, highlight BAV’s
substantial genetic heterogeneity and implicate
many discrete genes in its formation. Importantly,
BAV may not have been detected on the echocar-
diograms of index patients. Without deﬁnitive
phenotypic classiﬁcation of affected patients, linkage
analysis offers substantially diminished power and
has not generally succeeded in identifying genes that
cause BAV without aortic or extravascular manifes-
tations. NOTCH1 remains the only gene for isolated
BAV identiﬁed using linkage analysis and positional
cloning strategies, but it is unlikely to cause more
than a small proportion of familial cases (17,18).
In families with inherited BAV, the mutated gene
often correlates with speciﬁc features and prognosis.
ACTA2 mutations cause a syndrome that may include
BAV as well as thoracic aortic aneurysms, premature
coronary artery disease, and cerebrovascular disease
(19). NOTCH1 mutations predispose to BAV with
calciﬁc aortic stenosis but are not associated with
aortic disease or other extracardiac abnormalities.
BAV occurs in 20% of cases of Loeys-Dietz syndrome,
associated with craniofacial defects and connective
tissue fragility with vulnerability to acute arterial
dissections (20). Therefore, knowledge of the partic-
ular mutation in a family can direct clinicians to
screen for additional clinical features in the proband
and family members. As more BAV genes are
discovered, genetic information will increasingly in-
ﬂuence clinical decisions about diagnostic tests and
therapies for patients with BAV.
Studies involving large cohorts of patients with
BAV and thoracic aortic disease indicate that many
types of genetic variation contribute to the risk for this
complex disease, from common single-nucleotide
polymorphisms to rare copy-number variants and
chromosomal abnormalities (Fig. 1A). Mutations in the
same gene appear to cause TAAD across an allelic
TABLE 1 Human Genetic Syndromes That Include Bicuspid Aortic Valve
Syndrome Genetic Defect Clinical Features OMIM No.
Turner Monosomy X Short stature, infertility, coarctation —
Loeys-Dietz TGFBR1, TGFBR2 mutations TAAD, craniosynostosis, biﬁd uvula, skeletal defects 609192, 608967 (type 1)
610168, 610380 (type 2)
DiGeorge 22q11.2 deletion Truncus arteriosus, tetralogy of Fallot, craniofacial defects 188400 (DiGeorge)
192430 (VCF)
Familial TAAD ACTA2 mutations (10%–15%) TAAD, Premature coronary artery disease,
cerebral aneurysms
607086 (AAT1)
607087 (AAT2)
132900 (AAT4)
608967 (AAT5)
611788 (AAT6)
613780 (AAT7)
614816 (LDS type 4)
Andersen-Tawil KCNJ2 mutations (60%) Dysmorphic features, cardiac arrhythmias, periodic paralysis 170390 (LQTS 7)
Larsen FLNB mutations Craniofacial and skeletal defects 150250
Kabuki KMT2D, KDM6A mutations (70%) Mental retardation, hearing loss, coarctation 147920 (type 1)
300867 (type 2)
AAT ¼ aortic aneurysm, familial thoracic; LDS ¼ Loeys-Dietz syndrome; LQTS ¼ long-QT syndrome; OMIM ¼ Online Mendelian Inheritance in Man; TAAD ¼ thoracic aortic
aneurysms and dissections; VCF ¼ velocardiofacial syndrome.
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dromes to sporadic disease. For example, some muta-
tions inMYH11 cause autosomal-dominant inheritance
of TAAD associated with patent ductus arteriosus,
but rare duplications involving the same gene predis-
pose to isolated, nonfamilial cases of aortic dissection
(21–23). In the majority of these patients, the total
burden of genetic variants and environmental factors,
rather than a single variant or class of variants, con-
tributes to TAAD risk.
Because BAV and TAAD frequently occur together,
the genetic architecture of BAV may also consist of
many different genetic variants that interact in an
additive manner to increase risk for BAV and its
complications (Fig. 1B). Therefore, successful gene
discovery in BAV will require a combination of
different methods, such as linkage analysis, posi-
tional cloning, copy-number analysis, genome-wide
association (GWA) studies, and ultimately whole-
genome sequencing as its cost continues to decrease.
FEATURES OF BICUSPID AORTIC VALVE
THAT INFLUENCE GENE DISCOVERY
CLINICAL HETEROGENEITY. Reduced penetrance
and variable expressivity present major impediments
to identifying novel BAV genes in families (24). Thus,
some subjects who transmit BAV to their offspring
who are assumed to harbor causative genetic muta-
tions may not have BAV themselves or may have
other cardiovascular abnormalities. BAV disease also
displays remarkable variation in the age of onset of
complications, such as aortic valve disease or TAAD.
Although BAV formation is genetically determined,
the rate of progression to clinically evident disease orthe development of aortopathy may be driven by
interactions between genetic factors causing BAV,
genetic factors associated with the development of
aortic stenosis in tricuspid aortic valves, and well-
established cardiovascular risk factors such as
smoking, hypertension, and dyslipidemia (25,26).
These factors heavily inﬂuence valve calciﬁcation
leading to aortic stenosis or regurgitation (the most
common indications for valve replacement surgery in
patients with BAV) (27–30).
The interaction between genes and environment
in inﬂuencing aortic valve complications is also
apparent in mice, in which the development of
calciﬁc tricuspid aortic valve stenosis required both
dietary modiﬁcations and speciﬁc genetic mutations
(31). A recent GWA study demonstrated that an
intronic genetic variant at the lipoprotein(a) locus
promotes human aortic valve calciﬁcation (25).
Distinct genetic variants and environmental hazards,
independent of the factors that cause BAV formation,
may inﬂuence the complications and outcomes of
BAV disease and thus the recognition of BAV in an
individual patient.
ANIMAL MODELS. The paucity of animal studies
erects another obstacle to understanding BAV’s eti-
ology. It develops spontaneously in an inbred strain
of Syrian hamsters but without valve or aortic com-
plications typical of human BAV, and the underlying
genetic defect is unknown (32,33). Targeted deletions
of ﬁbroblast growth factor, bone morphogenetic
protein, and Notch pathway genes in mice produced
BAV with incomplete penetrance, as well as various
malformations of the LVOT and aorta (Table 2). This
approach, if sufﬁciently scaled to accommodate
the large numbers of BAV candidate genes and
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FIGURE 1 Genetic Variants on the Spectrum
(A) The diversity of genetic variants in the human genome. (Left) A single-nucleotide
variant at a speciﬁc location in the genome in 2 different individuals. Single-nucleotide
variants are classiﬁed as single-nucleotide polymorphisms (SNPs), which are found in 1%
or more of the general population, or rare variants, including disease-causing mutations.
(Right) A chromosomal duplication that results in a copy gain of a chromosomal segment.
Structural variants in the human genome include copy-number variants (CNVs) such as
duplications and deletions, as well as copy-neutral events such as inversions and trans-
locations. (B) The genetic spectrum of bicuspid aortic valve (BAV) disease. The allele
frequency equals the proportion of subjects harboring a genetic variant. Single-gene
disorders with high penetrance tend to cause genetic syndromes with BAV or familial forms
of BAV. Rare mutations such as CNVs are expected to cause early onset forms of BAV
with severe manifestations but may not be recognizable as genetic syndromes. Common
variation in genes that regulate aortic valve calciﬁcation or connective tissue integrity can
modify the phenotype of BAV disease progression but are unlikely to cause disease on their
own. Any combination of these variants may predispose to BAV in individual cases.
TAAD ¼ thoracic aortic aneurysms and dissections. Figure 1B is adapted from McCarthy MI,
Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits:
consensus, uncertainty and challenges. Nat Rev Genet 2008;9:356–69.
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835pathways, can help prioritize candidate genes for
further analysis.
However, with rare exceptions, mutations in genes
that cause BAV when targeted in animals have not
been found in humans with BAV. Therefore, typical
animal models with single gene mutations may not
be sufﬁcient, and incorporation of multiple muta-
tions or gene-environment interactions will likely
be required to understand the complexity of human
BAV disease.
CLINICAL IMPLICATIONS
Because BAV formation and disease involve many
genes, developing clinical genetic tests to identify
patients at risk for BAV-related complications, such
as aortic stenosis or TAAD, will require considerable
time and research. Until then, early identiﬁcation and
careful surveillance of at-risk family members will
likely remain primary clinical strategies. The 2010
American College of Cardiology and American Heart
Association guidelines for thoracic aortic disease
provide a class I indication to image ﬁrst-degree rel-
atives of patients with BAV and TAAD to detect
valvular and extravalvular complications (34,35).
Affected relatives can then receive interventions to
reduce traditional cardiovascular risk factors and,
perhaps, emerging therapies targeted to prevent
these complications. It is also recommended that
every newly diagnosed BAV patient undergo a
comprehensive clinical evaluation that includes
complete imaging, at a minimum, of the heart and
thoracic aorta to rule out other defects and additional
imaging as warranted by examination or family his-
tory. Genetic tests are offered to patients with BAV
when features of single-gene disorders or syndromes
are present, and ﬁndings are conﬁrmed in ﬁrst-
degree relatives whenever possible.
BICUSPID AORTIC VALVE GENETICS:
ROADMAP TO DISCOVERY
With so many issues to be resolved, how can we
unravel the genetic complexity of BAV? A proposed
roadmap for translational applications of genetic
discoveries is illustrated in the Central Illustration.
The International Bicuspid Aortic Valve Con-
sortium (BAVCon) (Online Appendix) was recently
founded to translate genetic discoveries into clini-
cally useful diagnostic tests and therapies, as well
as address broader challenges related to knowledge
gaps in the pathophysiology and natural history of
BAV disease. Designed as a registry for long-term
surveillance, BAVCon is conceptually similar to the
National Registry of Genetically Triggered ThoracicAortic Aneurysms and Cardiovascular Conditions
(GenTAC), which enrolled subjects with diverse
forms of thoracic aortic disease, including BAV.
The BAVCon Registry consists of independently
TABLE 2 Transgenic Mouse Models That Include Bicuspid Aortic Valve
Allele Penetrance Other Phenotypes Ref. #
Gata5tm1.1Nemr 7/28 LVH (47)
Tg(GATA5-cre)1Krc/Acvr1tm1Vk 3/22 Perimembranous VSDs (59)
Nos3tm1Unc 5/12 None (60)
Hoxa1tm3Mrc 4/17 IAA, VSD (61)
Tbx1tm1Pa 5/34 IAA, TOF, coronary anomalies (62)
Hoxa3tm1(cre)Moon/Fgf8tm2Moon 7/33 IAA, coronary anomalies (63)
Nkx2-5tm1(cre)Rjs/Frs2tm1Fwan 20% OA, DORV (64)
Nkx2-5tm1Wehi* Nkx2-5tm4Rph* 11/100 2/98 Conduction defects, PFO (65)
Allele information is taken from Mouse Genome Informatics (http://www.informatics.jax.org). *Heterozygotes.
DORV ¼ double-outlet right ventricle; IAA ¼ interrupted aortic arch; LVH ¼ left ventricular hypertrophy; OA ¼
overriding aorta; PFO ¼ patent foramen ovale; TOF ¼ tetralogy of Fallot; VSD ¼ ventricular septal defect.
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836arbitrated echocardiographic and computed tomo-
graphic images from more than 4,000 patients with
BAV and tricuspid controls retrospectively enrolled at
16 centers in North America and Europe. Prospective
collection of images and tissue samples from addi-
tional patients, and the eventual incorporation of
GenTAC patients with BAV into BAVCon, will create a
deeply phenotyped and collaborative resource for
clinical, genetic, and molecular studies available to
all BAVCon investigators.
The enormous diversity of BAV with respect to
anatomic variation, coexisting abnormalities, and
natural history poses a signiﬁcant challenge to re-
searchers whose goal is to identify genes that cause
BAV or predict BAV-associated complications. To sort
through this genetic complexity, large and ethnically
diverse cohorts that are well characterized inFunctional Studiesscovery
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re generated by introducing a speciﬁc human sequence variant into an
real time, these processes would most likely occur simultaneously.
us system; GWA ¼ genome-wide analysis.terms of BAV anatomy, associated complications, and
cardiovascular and noncardiovascular risk factors are
needed. BAVCon will permit adequately powered
GWA studies, which are particularly important for
understanding and predicting endpoints of BAV
disease, such as valve calciﬁcation and acute aortic
dissection.
Similarly, well-characterized families predisposed
to BAV and its complications inherited in a Mendelian
manner are needed to identify genes with mutations
that confer high disease risk. Investigators may need
to follow this cohort for a decade or longer to capture
outcomes, such as aortic valve stenosis, that are slow
to develop. Designed with these challenges in mind,
BAVCon represents the ﬁrst worldwide registry of
ethnically diverse patients with BAV characterized by
experts in the ﬁeld using stringent, uniform criteria
and standardized measurements. Valve morphology
and hemodynamic data will be precisely assessed
using state-of-the-art imaging methods and will be
correlated with these outcomes. Because different
genetic variants may contribute to outcomes, we
envision BAVCon as a rich and continuous source of
future genetic studies.
Large families with inherited predisposition to BAV
present the most promising opportunities for gene
discovery, because family based studies optimize the
statistical power to identify causative genetic vari-
ants. When BAV is inherited as an autosomal-
dominant trait, the mutant gene can be traced from
parents to offspring using segregation analysis, and
the causative mutations can then be identiﬁed by
sequencing the genes of distantly related subjects
(Fig. 2A). The ability to sequence entire exomes or
genomes of multiple family members has greatly
reduced the time and labor required for gene dis-
covery and has led to the discovery of several novel
genes for TAAD (21,36–39).
Even if BAV inheritance is not observed, genetic
tests of family members may still be informative.
Genetic variants present in affected children but not
their parents are referred to as de novo variants
(Fig. 2B), which are generally prioritized because they
tend to be more deleterious than inherited variations
(40). Recent trio-based exome sequencing studies
identiﬁed causal de novo mutations in several rare
syndromes that are not inherited in families (41,42).
Because dozens of de novo variants arise stochasti-
cally in each generation, candidate genes with de
novo variants need to be validated by performing
mutation analysis of independent groups of cases.
In contrast to families with inherited BAV disease,
>80% of patients with BAV have no known affected
relatives and are regarded as sporadic cases. Because
MT
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Cases Controls
WT WT WT
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A B
C
FIGURE 2 Experimental Designs to Identify Disease-Causing
and Susceptibility Genetic Variants
(A) Example of a 3-generation pedigree with autosomal-
dominant inheritance. Affected patients are gray. Mutation car-
riers (MT) and subjects without mutations (WT) are highlighted in
red and green, respectively. In this instance, the penetrance of
the mutation is complete, and the mutant gene can be mapped
to a segment of the genome using linkage analysis. (B) Example
of a trio. De novo mutations in the affected offspring that are not
found in the parents may be prioritized for analysis in indepen-
dent groups of cases. In this situation, the penetrance of the
phenotype in the parents is uncertain and may confound the
results. (C) Example of a case-control association study. The
genotypes of large groups of cases (gray) and controls (white)
are compared at sites across the genome. The red border iden-
tiﬁes subjects who carry the risk allele that is being tested for
association. Variants that are enriched in cases compared with
controls are considered to be associated with the disease. In this
case, there is a 4-fold enrichment of the variant among the cases
compared with controls.
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837linkage analysis is unfeasible to investigate single
genetic variants in unrelated patients, case-control
association methods such as GWA studies must be
used (Fig. 2C). GWA studies typically require thou-
sands of affected individuals and controls to generate
meaningful results and are measured by indirect as-
sociations between the genuine risk variants and
genotyped single-nucleotide polymorphisms, rather
than by direct identiﬁcation of the causal variants.
Thus, GWA studies are most likely to identify genetic
variants that increase susceptibility to BAV or its
complications. The size of the BAVCon cohort will
provide sufﬁcient power to discover these common
but low-impact BAV-associated variants.
Among sporadic BAV cases, patients at the severe
end of the BAV phenotypic spectrum are most likelyto have highly penetrant mutations in single genes
because they resemble patients with genetic syn-
dromes or inherited BAV. This includes patients
with unicuspid aortic valves, those with additional
congenitalmalformations, and thosewho require early
interventions for valve disease or TAADmanifesting in
childhood or adolescence. Genomic comparisons be-
tween these subgroups and older patients with BAV
without signiﬁcant valve or aortic complications can
uncover genetic variants that predispose to BAV-
associated complications. In normal populations,
these variants may only weakly inﬂuence the likeli-
hood of developing disease and may be difﬁcult to
detect, but the effects of these variants are likely to be
ampliﬁed in individuals with BAV, who tend to
develop more pronounced aortic disease at younger
ages. In other situations, this strategy of sampling at
the phenotypic extremes led to the discovery of indi-
vidually rare variants that would otherwise be missed
by traditional GWA studies (43–46).
Genetic studies may lead to the discovery of novel
genetic variants whose biological relevance to BAV
disease is unknown. Leveraging systems biology
to identify data patterns can help prioritize candi-
date genes. Systems analyses test associations of
biological pathways, rather than single genes, with
disease. For example, the discovery of NOTCH1
mutations in BAV families led to the systematic
investigation of Notch pathway genes in aortic valve
development and calciﬁcation (47–49). De novo
variants of genes that regulate histone modiﬁcation
were found to be enriched in patients with severe
congenital heart disease (50). These pathways and
others with relevance to BAV outcomes include
genes involved in aortic valve calciﬁcation, connec-
tive tissue integrity, and aortic disease. Using
systems-based approaches, BAV candidate genes can
be ranked according to their biological functions;
interacting genes in the same pathways can then be
screened for mutations in BAV cases by sequencing
or copy-number analysis.
Because BAV displays incomplete penetrance, a
substantial proportion of BAV-associated genetic
variants in sporadic cases may also be present in
apparently unaffected subjects. Therefore, indepen-
dent observations of genetic discoveries in separate
cohorts of patients with BAV will be essential for the
prioritization of candidate genes. With an enrollment
of several thousand patients, BAVCon will provide an
important platform for these types of validation
studies.
Despite signiﬁcant limitations in BAV animal
models, targeted gene deletions in mice, zebraﬁsh,
and cultured aortic valve interstitial cells have
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838provided useful insights into candidate gene in-
volvement in LVOT or aortic valve development
(3,51,52). Some of these methods can be developed
into high-throughput assays to screen candidate
genes for roles in BAV formation or disease pro-
gression. To investigate therapies for BAV-associated
complications, improved genetic models are needed.
“Knock-in” experiments, in which human mutations
are introduced into homologous mouse or zebraﬁsh
genes, may result in more faithful models of human
BAV phenotypes than current models with null muta-
tions (53). Pathobiological studies may complement
these strategies by validating candidate genes’ bio-
logical functions or identifying pathways that can be
explored using systems methods. These approaches
already have led to the discovery of new drug targets
and genetic tests for inherited cardiomyopathies, and
hold tremendous promise for BAV (54–56).
BACK TO THE BEDSIDE OF THE PATIENT
WITH BICUSPID AORTIC VALVE
How then do we translate these discoveries into
clinically meaningful tools for patients with BAV and
their families? One approach is to develop genetic
tests or biomarkers that identify patients with BAV
who are at high risk for adverse outcomes such as
aortic valve stenosis or TAAD. Selected patients with
BAV can then be enrolled into clinical trials to assessnovel preventative strategies or drug therapies on the
basis of their individualized genetic risk proﬁles.
Clinical trials will determine if selectively interfering
with these pathways using this targeted approach can
retard or prevent disease progression.
Similarly, genetic risk proﬁles may inﬂuence sur-
gical decisions. For example, young patients with
TAAD with normally functioning or mildly dysfunc-
tional BAVs frequently receive valve-sparing aortic
grafts, but we do not know which of them may
require future valve replacements or more distal
aortic repair (57,58). Genetic proﬁles may dictate
when valve replacements are indicated during aortic
repair and, most important, which aortas need to be
repaired at the time of valve replacement, a subject
of signiﬁcant current controversy. These are only 2
of many potential examples that illustrate the impact
of genetic discoveries on BAV diagnosis and thera-
pies. BAVCon will provide us with unprecedented
detail about subtypes of BAV disease through its
large and well-phenotyped cohort of patients, mak-
ing this type of comparative analysis possible for the
ﬁrst time.
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